Dapagliflozin Export Market Intelligence: India's 254 Suppliers Shipping to 113 Countries — TransData Nexus 2026

Q: Who are the top dapagliflozin exporters from India?

The top dapagliflozin exporters from India are: 1. AJANTA PHARMA LIMITED — $8.4M (17.1% market share); 2. MICRO LABS LIMITED — $7.7M (15.5% market share); 3. ALEMBIC PHARMACEUTICALS LIMITED — $6.1M (12.3% market share); 4. INVENTIA HEALTHCARE LIMITED — $4.6M (9.3% market share); 5. CIPLA LIMITED — $3.3M (6.6% market share). Together they account for 60.7% of India's total dapagliflozin export value.

Q: What is the total export value of dapagliflozin from India?

The total export value of dapagliflozin from India is $49.5M USD, recorded across 5,104 shipment transactions from 254 active exporters to 113 destination countries. The average shipment value is $9.7K.

Q: Which countries import dapagliflozin from India?

India exports dapagliflozin to 113 countries worldwide. The top importing countries are: CANADA (25.9% share, $12.8M), IRAQ (17.2% share, $8.5M), CHINA (5.6% share, $2.8M), NETHERLANDS (5.0% share, $2.5M), PHILIPPINES (4.8% share, $2.4M). These five markets account for 58.6% of total export value.

Q: What is the average price of dapagliflozin exports from India?

The average unit price for dapagliflozin exports from India is $11.25 USD per unit, with prices ranging from $0.01 to $2636.12 depending on formulation, packaging, and order volume. The total market is valued at $49.5M across 5,104 shipments.

Q: Which ports handle dapagliflozin exports from India?

The primary ports for dapagliflozin exports from India are SAHAR AIR (19.7% of shipments), SAHAR AIR CARGO ACC (INBOM4) (15.5% of shipments), DELHI AIR CARGO ACC (INDEL4) (14.9% of shipments), DELHI AIR (12.0% of shipments), Bombay Air (3.8% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of dapagliflozin?

India is one of the world's leading exporters of dapagliflozin due to its large base of 254 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports dapagliflozin to 113 countries, demonstrating 58% global market coverage.

Q: What certifications do Indian dapagliflozin exporters need?

Indian dapagliflozin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import dapagliflozin from India?

There are 502 registered buyers importing dapagliflozin from India, spread across 113 countries. The repeat buyer rate is 70.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top dapagliflozin supplier from India?

AJANTA PHARMA LIMITED is the leading dapagliflozin exporter from India with a market share of 17.1% and total export value of $8.4M across 103 shipments. The top 5 suppliers together control 60.7% of total export value.

Suresh Sormare

Dapagliflozin

India Pharmaceutical Trade Intelligence

$49.5M254 Suppliers113 CountriesHS 30049099

ExportsIndia → CANADA25.9%India → IRAQ17.2%

ImportsGERMANY → India$59.4K BRAZIL → India$38.8K

#1 Supplier: AJANTA PHARMA

Dapagliflozin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Dapagliflozin to the World

Between 2022 and 2026, India exported $49.5M worth of dapagliflozin across 5,104 verified shipments to 113 countries — covering 58% of world markets in the Advanced Diabetes Medications segment. The largest destination is CANADA (25.9%). AJANTA PHARMA LIMITED leads with a 17.1% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published May 2026·Updated May 2026·

Dapagliflozin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Dapagliflozin export data snapshot — $49.5M · 254 exporters · 113 countriesTransData Nexus · Indian Customs Data

Top Dapagliflozin Exporters from India

254 active exporters · Ranked by export value

View all 254 →

Top Dapagliflozin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	AJANTA PHARMA LIMITED	$8.4M	103	4	17.1%
2	MICRO LABS LIMITED

Top Countries Importing Dapagliflozin from India

113 destination markets · Ranked by import value

All 113 countries →

Top Countries Importing Dapagliflozin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	CANADA	$12.8M	25.9%
2	IRAQ	$8.5M	17.2%
3	CHINA	$2.8M	5.6%
4	NETHERLANDS	$2.5M	5.0%
5	PHILIPPINES	$2.4M	4.8%
6	MAURITIUS	$2.3M	4.7%
7	NIGERIA	$1.3M	2.7%
8	SAUDI ARABIA	$1.2M	2.4%
9	ICELAND	$1.1M	2.2%
10	UGANDA	$923.7K	1.9%

CANADA is India's largest dapagliflozin export destination, absorbing 25.9% of total exports worth $12.8M. The top 5 importing countries — CANADA, IRAQ, CHINA, NETHERLANDS, PHILIPPINES — together account for 58.6% of India's total dapagliflozin export value. The remaining 108 destination countries collectively receive the other 41.4%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Dapagliflozin to India?

28 origin countries · Total import value: $8057.2B

India imports dapagliflozin from 28 countries with a combined import value of $8057.2B. The largest supplier is UNITED STATES ($8057.2B, 184 shipments), followed by SWEDEN and SWITZERLAND. All values are from Indian Customs (DGFT) import records.

Countries Supplying Dapagliflozin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$8057.2B	184	100.0%
2	SWEDEN	$942.7K	16	0.0%
3	SWITZERLAND	$119.4K	6	0.0%
4	GERMANY	$59.4K	59	0.0%
5	BRAZIL	$38.8K	30	0.0%
6	UNITED KINGDOM	$38.7K	21	0.0%
7	AUSTRALIA	$31.6K	16	0.0%
8	SLOVENIA	$27.0K	6	0.0%
9	IRELAND	$12.9K	10	0.0%
10	BULGARIA	$12.3K	7	0.0%

Showing top 10 of 28 origin countries

UNITED STATES is the largest supplier of dapagliflozin to India, accounting for 100.0% of total import value. The top 5 origin countries — UNITED STATES, SWEDEN, SWITZERLAND, GERMANY, BRAZIL — together supply 100.0% of India's dapagliflozin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Dapagliflozin — Export Intelligence Video

Visual overview of India's dapagliflozin import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's dapagliflozin pharmaceutical import and export market — $49.5M in total trade, 254 verified manufacturers, and 113 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Dapagliflozin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is approved in the United States for the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for dapagliflozin, indicating the presence of generic versions in the market. The most recent approval was granted in March 2023. As of March 2026, there are no active FDA import alerts specifically targeting dapagliflozin, suggesting compliance with regulatory standards.

India's significant role in the pharmaceutical supply chain is evident, with 254 active exporters contributing to a total export value of $49.5 million USD for dapagliflozin between 2022 and 2026. This robust exporter base underscores India's capacity to meet the demand for dapagliflozin in the U.S. market.

2EU & UK Regulatory Framework

In the European Union, dapagliflozin is marketed under the brand name Forxiga and has been authorized since November 2012. The European Medicines Agency (EMA) approved a generic version, Dapagliflozin Viatris, on 24 March 2023. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of dapagliflozin-containing products. Notably, in December 2021, the MHRA announced the withdrawal of dapagliflozin's indication for type 1 diabetes mellitus, a decision based on commercial considerations rather than new safety concerns. (gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to the EU and UK. This includes adherence to stringent quality standards and regular inspections to ensure product safety and efficacy.

3WHO Essential Medicines & Global Standards

Dapagliflozin is included in the World Health Organization's Model List of Essential Medicines, reflecting its importance in managing type 2 diabetes mellitus. The drug is subject to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

4India Regulatory Classification

In India, dapagliflozin is classified under Schedule H, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines, including dapagliflozin. As of March 2026, the ceiling price for dapagliflozin has been set to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

5Patent & Exclusivity Status

The primary patent for dapagliflozin has expired, allowing for the introduction of generic versions into the market. This has led to increased competition among manufacturers, contributing to the availability of more affordable treatment options for patients.

6Recent Industry Developments

In July 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the extension of the indication for Invokana (canagliflozin) to include treatment of children from 10 years of age with type 2 diabetes mellitus. (ema.europa.eu)

In November 2023, the CHMP adopted a positive opinion recommending the extension of the indication for Jardiance (empagliflozin) to include the treatment of chronic kidney disease in adults. (ema.europa.eu)

These developments reflect the evolving regulatory landscape and the expanding therapeutic applications of SGLT2 inhibitors, including dapagliflozin, in managing various health conditions.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Dapagliflozin

Retail & reference prices across 9 markets vs. India FOB export price of $11.25/unit

Global Price Benchmark for Dapagliflozin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	Data not available	USD	Specific pricing data for dapagliflozin in the United States is not readily available from public government sources.
United Kingdom	$1.71	GBP	According to the British National Formulary (BNF), the average price per day of treatment with dapagliflozin is approximately $1.71. (cdn.who.int)
Germany	Data not available	EUR	Specific pricing data for dapagliflozin in Germany is not readily available from public government sources.
Australia

Supply Chain Risk Assessment — Dapagliflozin

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, while a major producer of Active Pharmaceutical Ingredients (APIs), remains significantly dependent on China for Key Starting Materials (KSMs). As of 2024, approximately 35% of India's API requirements were met through imports, with a substantial portion sourced from China. This reliance exposes the supply chain to vulnerabilities, particularly when geopolitical tensions or trade disruptions arise.

The closure of the Strait of Hormuz in March 2026, a critical chokepoint for global oil and gas shipments, has further exacerbated supply chain challenges. The blockade has led to surging energy costs and logistical disruptions, impacting the availability and pricing of essential raw materials for pharmaceutical manufacturing. These developments underscore the pressing need for India to bolster its domestic production capabilities for KSMs and APIs to mitigate external dependencies.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five exporters of Dapagliflozin from India account for 60.7% of the total export value, with AJANTA PHARMA LIMITED leading at a 17.1% share. This high supplier concentration poses a significant risk, as disruptions affecting any of these key players could severely impact the global supply of Dapagliflozin.

To address such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) Scheme, aiming to enhance domestic manufacturing of APIs and reduce reliance on imports. The PLI scheme incentivizes local production of 41 identified APIs, including those critical for various therapeutic categories. (pharmanow.live) While this initiative is a step toward supply chain resilience, its effectiveness in diversifying the supplier base for Dapagliflozin remains to be fully realized.

Access Complete Dapagliflozin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 5,104 transactions across 113 markets.

Request Demo View Pricing

Frequently Asked Questions — Dapagliflozin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top dapagliflozin exporters from India?

The leading dapagliflozin exporters from India are AJANTA PHARMA LIMITED, MICRO LABS LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, and 12 others. AJANTA PHARMA LIMITED leads with 17.1% market share ($8.4M). The top 5 suppliers together control 60.7% of total export value.

What is the total export value of dapagliflozin from India?

The total export value of dapagliflozin from India is $49.5M, recorded across 5,104 shipments from 254 active exporters to 113 countries. The average shipment value is $9.7K.

Which countries import dapagliflozin from India?

India exports dapagliflozin to 113 countries. The top importing countries are CANADA (25.9%), IRAQ (17.2%), CHINA (5.6%), NETHERLANDS (5.0%), PHILIPPINES (4.8%), which together account for 58.6% of total export value.

What is the HS code for dapagliflozin exports from India?

The primary HS code for dapagliflozin exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Dapagliflozin

Dapagliflozin

Top Dapagliflozin Exporters from India

Top Countries Importing Dapagliflozin from India

Who Supplies Dapagliflozin to India?

Quick Facts

Related Advanced Diabetes Medications

Related Analysis

Need Details?

Dapagliflozin — Export Intelligence Video

Regulatory Landscape — Dapagliflozin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Dapagliflozin

Supply Chain Risk Assessment — Dapagliflozin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Dapagliflozin Trade Intelligence

Frequently Asked Questions — Dapagliflozin Exports from India

Who are the top dapagliflozin exporters from India?

What is the total export value of dapagliflozin from India?

Which countries import dapagliflozin from India?

What is the HS code for dapagliflozin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of dapagliflozin exports from India?

Which ports handle dapagliflozin exports from India?

Why is India a leading exporter of dapagliflozin?

What certifications do Indian dapagliflozin exporters need?

How many buyers import dapagliflozin from India?

What is the market share of the top dapagliflozin exporter from India?

Analysis Methodology